S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Amyris, Inc. (NASDAQ:AMRS) Expected to Post Quarterly Sales of $61.73 Million

Monday, January 10, 2022 | MarketBeat

Wall Street analysts expect that Amyris, Inc. (NASDAQ:AMRS) will announce sales of $61.73 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Amyris' earnings, with the lowest sales estimate coming in at $52.90 million and the highest estimate coming in at $83.00 million. Amyris reported sales of $79.74 million in the same quarter last year, which would suggest a negative year over year growth rate of 22.6%. The company is expected to issue its next quarterly earnings results on Tuesday, March 1st.

On average, analysts expect that Amyris will report full year sales of $338.01 million for the current fiscal year, with estimates ranging from $330.00 million to $360.00 million. For the next year, analysts anticipate that the company will post sales of $379.09 million, with estimates ranging from $330.00 million to $436.40 million. Zacks Investment Research's sales calculations are a mean average based on a survey of research analysts that cover Amyris.

Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Monday, November 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The firm had revenue of $47.90 million for the quarter, compared to analysts' expectations of $64.21 million. The business's quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.41) EPS.

Several equities research analysts have recently issued reports on the company. Cowen assumed coverage on Amyris in a research note on Friday, October 15th. They issued a $19.00 price objective for the company. Roth Capital lowered their price objective on Amyris from $22.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, November 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Amyris has a consensus rating of "Buy" and a consensus price target of $22.00.

In other Amyris news, Director James F. Mccann purchased 17,400 shares of the firm's stock in a transaction that occurred on Monday, December 6th. The stock was purchased at an average cost of $5.71 per share, with a total value of $99,354.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 36.30% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMRS. Nisa Investment Advisors LLC purchased a new position in shares of Amyris in the 2nd quarter valued at $28,000. FORA Capital LLC purchased a new position in Amyris during the 2nd quarter worth $29,000. Rockefeller Capital Management L.P. purchased a new position in Amyris during the 3rd quarter worth $65,000. Meeder Asset Management Inc. grew its stake in Amyris by 71.8% during the 2nd quarter. Meeder Asset Management Inc. now owns 5,099 shares of the biotechnology company's stock worth $83,000 after buying an additional 2,131 shares during the last quarter. Finally, Islay Capital Management LLC purchased a new position in Amyris during the 3rd quarter worth $101,000. Institutional investors own 44.29% of the company's stock.

NASDAQ:AMRS opened at $4.59 on Monday. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -2.35 and a beta of 1.51. Amyris has a 1 year low of $4.37 and a 1 year high of $23.42. The business has a 50 day simple moving average of $7.11 and a 200-day simple moving average of $11.74.

Amyris Company Profile

Amyris, Inc engages in the provision of bioscience solutions. It offers its products to health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Recommended Story: What does a neutral rating on stocks mean?

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Amyris right now?

Before you consider Amyris, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amyris wasn't on the list.

While Amyris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here



Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.